For most types of cancer, determining the stage (extent) of the cancer is very important. The stage is based on the size of the tumor and how far the cancer has spread. This can be helpful in predicting a person’s outlook and deciding on treatment.
Acute myeloid leukemia (AML), on the other hand, does not usually form tumors. It generally is in all of the bone marrow in the body and, in some cases, has spread to other organs, such as the liver and spleen. Therefore AML is not staged like most other cancers. The outlook for a person with AML depends instead on other information, such as the subtype of AML (determined by lab tests), the patient’s age, and other lab test results.
Knowing the subtype of AML can be very important, as it sometimes affects both a patient’s outlook and the best treatment. For example, the acute promyelocytic leukemia (APL) subtype is often treated using drugs that are different from those used for other subtypes of AML.
Two of the main systems that have been used to classify AML into subtypes are the French-American-British (FAB) classification and the newer World Health Organization (WHO) classification.
The French-American-British (FAB) classification of AML
In the 1970s, a group of French, American, and British leukemia experts divided AML into subtypes, M0 through M7, based on the type of cell from which the leukemia develops and how mature the cells are. This was based largely on how the leukemia cells looked under the microscope after routine staining.
Undifferentiated acute myeloblastic leukemia
Acute myeloblastic leukemia with minimal maturation
Acute myeloblastic leukemia with maturation
Acute promyelocytic leukemia (APL)
Acute myelomonocytic leukemia
Acute myelomonocytic leukemia with eosinophilia
Acute megakaryoblastic leukemia
Subtypes M0 through M5 all start in immature forms of white blood cells. M6 AML starts in very immature forms of red blood cells, while M7 AML starts in immature forms of cells that make platelets.
World Health Organization (WHO) classification of AML
The FAB classification system is useful and is still commonly used to group AML into subtypes. But it doesn’t take into account many of the factors that are now known to affect prognosis (outlook). The World Health Organization (WHO) has developed a newer system that includes some of these factors to try to better classify AML.
The WHO system divides AML into several groups:
AML with certain genetic abnormalities
- AML with a translocation between chromosomes 8 and 21
- AML with a translocation or inversion in chromosome 16
- AML with a translocation between chromosomes 9 and 11
- APL (M3) with a translocation between chromosomes 15 and 17
- AML with a translocation between chromosomes 6 and 9
- AML with a translocation or inversion in chromosome 3
- AML (megakaryoblastic) with a translocation between chromosomes 1 and 22
AML with myelodysplasia-related changes
AML related to previous chemotherapy or radiation
AML not otherwise specified (This includes cases of AML that don’t fall into one of the above groups, and is similar to the FAB classification.)
- AML with minimal differentiation (M0)
- AML without maturation (M1)
- AML with maturation (M2)
- Acute myelomonocytic leukemia (M4)
- Acute monocytic leukemia (M5)
- Acute erythroid leukemia (M6)
- Acute megakaryoblastic leukemia (M7)
- Acute basophilic leukemia
- Acute panmyelosis with fibrosis
Myeloid sarcoma (also known as granulocytic sarcoma or chloroma)
Myeloid proliferations related to Down syndrome
Undifferentiated and biphenotypic acute leukemias (leukemias that have both lymphocytic and myeloid features). Sometimes called ALL with myeloid markers, AML with lymphoid markers, or mixed phenotype acute leukemias.
Prognostic factors for acute myeloid leukemia
In recent years, research has focused on why some patients have a better chance to be cured than others. Differences among patients (or their leukemias) that affect response to treatment are called prognostic factors. Prognostic factors help doctors decide if people with a certain type of AML should get more or less treatment. Some of these include:
AML cells can have many kinds of chromosome changes, some of which can affect a person’s prognosis. Those listed below are some of the most common, but there are many others. Not all patients have these abnormalities. Patients without any of these usually have an outlook that is between favorable and unfavorable.
- Translocation between chromosomes 8 and 21 (seen most often in patients with M2)
- Inversion of chromosome 16 (seen most often in patients with M4 eos) or a translocation between chromosome 16 and itself
- Translocation between chromosomes 15 and 17 (seen most often in patients with M3)
- Deletion (loss) of part of chromosome 5 or 7 (no specific AML type)
- Translocation or inversion of chromosome 3
- Translocation between chromosomes 6 and 9
- Translocation between chromosomes 9 and 22
- Abnormalities of chromosome 11 (at the spot q23)
- Complex changes - those involving several chromosomes (no specific AML type)
People whose leukemia cells have certain gene mutations may have a better or worse outlook.
For instance, about 1 patient out of 3 with AML has a mutation in the FLT3 gene. These people tend to have a poorer outcome, but new drugs that target this abnormal gene are now being studied, which may lead to better outcomes.
On the other hand, people with changes in the NPM1 gene (and no other abnormalities) seem to have a better prognosis than people without this change. Changes in the CEBPA gene are also linked to a better outcome.
In the coming years, doctors will use newer lab tests to learn more about the underlying genetic defects that cause AML and how they can be used to predict a patient’s prognosis. These genetic defects might also form the basis for treating these leukemias.
Markers on the leukemia cells
If the leukemia cells have the CD34 protein and/or the P-glycoprotein (MDR1 gene product) on their surface, it is linked to a worse outcome.
Older patients (over 60) generally don’t do as well as younger patients. Some of this may be because they are more likely to have unfavorable chromosome abnormalities. Older patients sometimes also have other medical conditions that can make it harder to treat them with more intense chemotherapy regimens.
White blood cell count
A high white blood cell count (>100,000) at the time of diagnosis is linked to a worse outlook.
Prior blood disorder leading to AML
Having a prior blood disorder such as a myelodysplastic syndrome is linked to a worse outcome.
AML that develops after treatment for another cancer tends is linked to a worse outcome.
Having an active systemic (blood) infection at the time of diagnosis makes a poor outcome more likely.
Leukemia cells in the central nervous system
Leukemia that has spread to the area around the brain and spinal cord can be hard to treat, since most chemotherapy drugs can’t reach that area.
Status of acute myeloid leukemia after treatment
Not surprisingly, how well (and how quickly) the leukemia responds to treatment also affects long-term prognosis. Better responses have been linked with better long-term outcomes.
A remission (complete remission) is usually defined as having no evidence of disease after treatment. This means the bone marrow contains fewer than 5% blast cells, the blood cell counts are within normal limits, and there are no signs or symptoms of the disease. A molecular complete remission means there is no evidence of leukemia cells in the bone marrow, even when using very sensitive tests, such as PCR (polymerase chain reaction).
Minimal residual disease is a term used after treatment when leukemia cells can’t be found in the bone marrow using standard tests (such as looking at cells under a microscope), but more sensitive tests (such as flow cytometry or PCR) find evidence that there are still leukemia cells in the bone marrow.
Active disease means that either there is evidence that the leukemia is still present during treatment or that the disease has come back after treatment (relapsed). For a patient to have relapsed, they must have more than 5% blast cells in their bone marrow.
Acute myeloid leukemia (AML), also known as acute nonlymphocytic leukemia, represents a group of clonal hematopoietic stem cell disorders in which both a block in differentiation and unchecked proliferation result in the accumulation of myeloblasts at the expense of normal hematopoietic precursors. It is the most common acute leukemia in adults.
Back to Top
There are a number of risk factors for the development of AML.
Chromosomal instability in several autosomal dominant conditions can lead to AML, including Fanconi's anemia, ataxia-telangiectasia, neurofibromatosis, and Bloom's syndrome. Germline mutations in the AML-1 gene are known to be associated with an increased risk of the development of AML. Additionally, congenital disorders, including infantile X-linked agammaglobulinemia and Down's syndrome, have also been associated with an increased incidence of AML.
Ionizing radiation and organic solvents such as benzene and other petroleum products have been associated with a higher risk of developing AML. Both ras mutations and polymorphisms resulting in the inactivation of nicotinamide adenine dinucleotide phosphate (NADPH) and reduced NADPH-quinone oxidoreductase have been found in patients with these exposures. Increased incidence of leukemia is proportional to the cumulative dose of radiation. Doses less than 100 cGy are not typically associated with leukemia.
Therapy-related AML typically develops after alkylating agent-induced damage at a median of 5 to 7 years after therapy for the primary malignancy. It is usually associated with an antecedent myelodysplastic disorder. DNA topoisomerase II agents may also produce gene rearrangements leading to AML, with a short latency period of 12 to 18 months following treatment. The latency between exposure to radiation therapy for other cancers and AML development is similar to that of alkylating agents.
Prior Bone Marrow Disorders
Secondary AML can develop in patients with various hematologic disorders, such as aplastic anemia, paroxysmal nocturnal hemoglobinuria, and severe congenital neutropenia. Other inherited hematologic conditions have also been implicated, such as Bloom's syndrome and Fanconi's anemia. Myelodysplastic and myeloproliferative syndromes, present for at least 3 months, can also progress to AML.
The incidence rate of AML increases with age. In the United States, the median age of patients with AML is 67 years. The age-adjusted population incidence is 12.2 per 100,000 for people older than 65 years, compared with 1.3 per 100,000 for those younger than 65 years. Similarly, chromosomal abnormalities occur with greater frequency among this older population of patients.
Back to Top
In AML, the normal process of hematopoietic cell differentiation is interrupted in those cells committed to the myeloid lineage. Some reports have supported the concept of a single transformed hematopoietic stem cell, whereas others have contended that transformation can occur at any point from stem cell to lineage-committed progenitor cell. This transformation can occur either as a de novo event, or in association with previous therapy, and in most cases likely results from multiple genetic events.
Several molecular and genetic lesions have been identified in AML, leading to advances in defining its pathogenesis. The most familiar of these is the t(15;17) translocation, resulting in AML with abnormal promyelocytes, known as acute promyelocytic leukemia (APL). Translocation of these chromosomes results in the fusion of the PML gene on chromosome 15, with the retinoic acid receptor gene alpha (RARA) on chromosome 17, giving rise to a fusion product (PML/RARA) that prevents differentiation to mature granulocytes. This block in differentiation can be overcome with all-trans retinoic acid (ATRA), a vitamin A derivative. The DNA-binding subunit core-binding factor β (CBF β) produces a transcription factor that regulates numerous hematopoietic-specific genes. The genetic translocations t(8;21), inv(16), and t(16;16) have all been associated with this transcription factor. AML patients with these genetic disorders have a better prognosis. Six percent to 8% of patients with AML have structural alterations of 11q23, leading to the MLL rearrangement. The MLL gene rearrangement, also known as mixed lineage leukemia, may lead to AML composed of both myeloid and lymphoid cells. The MLL gene rearrangement portends a worse outcome in patients with AML.
Back to Top
Signs and Symptoms
AML often manifests with clinical sequelae attributable to pancytopenia. The deficient production of red blood cells can lead to patient complaints of weakness, fatigue, or dyspnea on exertion. Pallor is a common finding on physical examination. Infection can result from insufficient numbers of white cells or impaired white blood cell function. Collections of leukemic cells, seen in leukemia cutis, granulocytic sarcomas, or chloromas, can also occur. These collections represent extramedullary sites of disease and often involve cutaneous and visceral tissues. In some cases, hyperleukocytosis can lead to ocular, cardiac, pulmonary, or cerebral dysfunction. Low numbers of platelets can lead to petechiae, gingival bleeding, ecchymosis, epistaxis, or menorrhagia. APL is a distinct entity of AML that often manifests with hemorrhagic complications, including disseminated intravascular coagulation. Palpable lymphadenopathy and hepatosplenomegaly are rare findings in AML. It is typical for patients to complain of flu-like symptoms for 4 to 6 weeks before the diagnosis.
In some patients, the diagnosis of AML can constitute a medical emergency, making prompt referral to a medical hematologist or oncologist a requisite. Hyperleukocytosis, leukostasis, or both can cause impairment of blood flow, most often resulting in central nervous system (CNS) or pulmonary symptoms. Rapid lowering of the white blood cell count can be achieved with the institution of chemotherapy, leukapheresis, or low-dose radiation. CNS leukemia, although less common in AML, can manifest with patient complaints of headache, lethargy, or cranial nerve signs. For these patients, intrathecal chemotherapy or cranial radiation are treatment options. Additionally, metabolic abnormalities, including tumor lysis syndrome, can occur spontaneously because of high tumor burden or as a result of cytotoxic chemotherapy. AML should always be considered a medical emergency in younger (age <60 years) adults, in whom each day of delay in instituting definitive chemotherapy may compromise survival.
Back to Top
The diagnosis of AML requires the identification of 20% or more leukemic blasts in the bone marrow. Further analysis then must separate AML from acute lymphoblastic leukemia by showing evidence for commitment to the myeloid lineage. Immunohistochemical staining for myeloperoxidase is the best method for determining which cells are committed to the myeloid lineage (Figure 1). The leukemic clone giving rise to AML can occur at any point in the differentiation of the myeloid cell, creating heterogeneity among patients. Flow cytometry and cytogenetics are then used to differentiate the various AML subtypes.
The subtypes of AML were previously described as M0 through M7 by the French-American-British (FAB) system (Box 1). In 1997, however, the World Health Organization (WHO) reclassified AML into four categories (Box 1) in an attempt to predict the prognosis and biologic properties of AML subcategories more accurately and to enhance the clinical relevance of the system. This new classification reflected those entities with similar biologic and clinical features. It also takes into account the morphologic, genetic, and immunophenotypic features of the disease entities. The four categories include AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related AML, and AML not otherwise specified, which roughly correlates with the FAB classification (Figures 2 and 3). The WHO classification system differs from the FAB system in that the previous blast cell threshold of 30% for the diagnosis of AML has been reduced to 20%, and patients with recurring cytogenetic abnormalities are now classified as having AML regardless of blast percentage.
Box 1: Classification of Acute Myeloid Leukemia
|M0: Myeloblastic without maturation|
|M1: Myeloblastic with minimal maturation|
|M2: Myeloblastic with maturation|
|M3: Promyelocytic; M3v: Promyelocytic ("microgranular")|
|M4: Myelomonocytic; M4 Eo: Myeloblastic with abnormal eosinophils (Eo)|
|M5: Monocytic: poorly (M5a) or well differentiated (M5b)|
|World Health Organization Classification|
|Acute myeloid leukemia with recurrent genetic abnormalities|
|Acute myeloid leukemia with myelodysplasia-related changes|
|Therapy-related myeloid neoplasms|
|Acute myeloid leukemia, not otherwise specified|
Adapted with permission from the American Society of Hematology (Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937–951); permission conveyed through Copyright Clearance Center, Inc.
Box 2 presents the laboratory and imaging studies needed to diagnose and ultimately treat patients with AML accurately. Baseline evaluation involves routine blood work, including a complete blood count with differential, comprehensive metabolic profile, and coagulation studies. A bone marrow aspiration and biopsy should be evaluated by cytochemistry, immunophenotyping, flow cytometry, and cytogenetics; this is necessary for determining diagnosis and prognosis. Additional studies, including chest radiography and echocardiography are needed to determine a patient's ability to receive potentially cardiotoxic chemotherapy. A lumbar puncture may be needed if CNS symptoms are identified. Human leukocyte antigen (HLA) typing is needed if bone marrow transplantation is being considered, and it should be performed prior to myeloablation.
Box 2: Routine Testing for Diagnosis and Treatment of Acute Myeloid Leukemia
|Complete blood cell count with differential|
|Determination of the following:|
|Partial thromboplastin time, activated partial thromboplastin time, fibrinogen, D dimer|
|Bone marrow biopsy with cytochemistry, immunophenotyping, flow cytometry, cytogenetics|
|Lumbar puncture in symptomatic patients|
|Human leukocyte antigen typing of patient and siblings|
|Herpes simplex and cytomegalovirus serology|
The British Medical Research Council (MRC) AML 10 trial and a Cancer and Leukemia Group B (CALGB) trial found that patients could then be categorized prognostically based on their pretreatment cytogenetics. Patients could be separated into distinct cytogenetic categories based on response to induction treatment, relapse risk, and overall survival: favorable, intermediate (I and II), and adverse cytogenetic groups (Box 3). Typically, patients with favorable-risk cytogenetics have abnormalities of the AML1-CBFβ DNA subunit. This subunit is composed of two proteins, AML1 (also known as CBF 2α, CBF2α) which heterodimerizes with another protein, CBFβ, to form a transcription factor necessary for normal hematopoiesis. Adverse cytogenetics include complex (three or more) abnormalities, deletion of 5q, abnormal 3q, and deletion of chromosome 7. Thus, it is crucial to test for cytogenetics and, when applicable, to use fluorescence in situ hybridization, because these may help dictate therapy. More recently, gene expression profiling has been shown to improve the molecular classification and prediction of outcome in patients with AML. More recently, molecular profiling has become standard among patients with "normal" cytogenetics, to further distinguish good from poor prognostic groups within these patients. These include assessment for the nucleophosmin1 (NPM1) mutation, considered good risk; FMS-like tyrosine kinase-3 (FLT3) mutations, considered poor-risk; and the CCAAT/enhancer-binding protein-alpha (CEBPα) mutation, considered good-risk. A number of other mutations, including ASXL1, TET2, IDH1/2, DNMT3A, have also been associated with prognosis, though at the time of this writing, have not been incorporated into standard clinical practice.
Box 3: Cytogenetic Risk Stratification for Overall Survival
|Balanced structural rearrangements|
|Balanced structural rearrangements|
|Cytogenetics abnormalities not classified as favorable or adverse|
|Balanced structural rearrangements|
|Unbalanced structural rearrangement|
Data from Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453–474.
Back to Top
Therapy for AML includes remission induction followed by postremission chemotherapy for most patients. For some, this is followed by hematopoietic stem cell transplantation (HSCT) (see later). Treatment recommendations for AML vary, taking into account patient age, cytogenetics, and prognostic factors. The recommendations are often divided into those for patients younger than 60 and those 60 years and older (Table 1).
Table 1: Treatment-Related Statistics for Acute Myeloid Leukemia Stratified by Age
|Induction chemotherapy||7 + 3||7 + 3|
|Postremission chemotherapy||HiDAC||5 or 5 + 2|
|Complete response rates (%)||60-85||40-55|
|Treatment-related mortality (%)||5-10||20-30|
|5-year disease-free survival (%)||30||5-10|
HiDAC, high-dose cytarabine (1,000-3,000 mg/m2 IV over 1-3 hours every 12 hours for 6 to 12 doses); 7 + 3, 7 days of cytarabine at 100 mg/m2 plus 3 days of an anthracycline or anthracenedione (most commonly idarubicin, 12 mg/m2, mitoxantrone, 12 mg/m2, or daunorubicin, 45 mg/m2); 5 or 5 + 2, 5 days of cytarabine at 100 mg/m2 alone or combined with 2 days of an anthracycline or anthracenedione.
The goal of induction chemotherapy is to reduce the number of leukemic cells, as well as to return proper function to the bone marrow. The 7 + 3 regimen of cytarabine (100 mg/m2 for 7 days plus an anthracycline or anthracenedione [most often daunorubicin, 45 mg/m2 in older adults, 90mg/m2 in younger adults, but other options include idarubicin or mitoxantrone 12 mg/m2] for 3 days) is the most common induction regimen. Potential toxicities of induction therapy include: tumor lysis syndrome, cardiac abnormalities (electrocardiographic changes, arrhythmias, or congestive heart failure), tissue necrosis (anthracycline chemotherapy is considered a vesicant), pancytopenia, nausea and vomiting, alopecia, and death, among others. Commonly, a bone marrow biopsy will be repeated 2 weeks following the initiation of therapy, to assess marrow aplasia. If residual leukemia is detected, patients are treated with another chemotherapy course, termed reinduction.
Postremission chemotherapy then aims to eradicate any residual disease in an attempt at cure. Postremission chemotherapy includes high-dose cytarabine (ara-c; HiDAC) for patients younger than 60 years, in whom a survival advantage has been demonstrated with this therapy, particularly in patients with good-risk, core binding factor cytogenetic abnormalities. In patients younger than 60 years, HiDAC yields a 4-year disease-free survival rate of 44%, but carries with it a 5% treatment-related mortality. In contrast, HiDAC failed to improve the outcome of patients older than 60 years (15% disease-free survival at 4 years). The HiDAC regimen is 1,000 to 3,000 mg/m2 IV over 1 to 3 hours every 12 hours for 6 to 12 doses. High doses of cytarabine can be associated with cerebellar, ophthalmologic, and gastrointestinal toxicity, particularly in patients over the age of 60 years.
The treatment of older AML patients is controversial. Older adults often cannot tolerate the toxicities of intensive remission induction chemotherapy. With the typical treatment plans, the treatment-related mortality is between 15% and 30%. Other less intensive regimens that may be used are oral agents (such as hydroxyurea), "low dose cytarabine" (20 mg/m2 subcutaneous injection twice daily for 10 days), or one of the hypomethylating agents (azacitidine or decitabine). These are associated with less of a myelosuppressive effect, lower treatment-related mortality, and less time spent in the hospital.
Allogeneic bone marrow transplantation is an additional option for postremission therapy in adults with AML. For some patients younger than 60 years with poor-risk disease features (such as adverse cytogenetics) and for whom an HLA-matched sibling or matched unrelated donor is available, allogeneic stem cell transplantation should follow induction chemotherapy. This procedure is not without risk; it has an associated 20% to 25% treatment-related mortality rate. Furthermore, the majority of studies fail to reveal any survival advantage for allogeneic transplantation in good risk cytogenetics. Those patients with unfavorable cytogenetics have a high-risk for relapse with chemotherapy alone and may receive maximum benefit from allogeneic transplantation following remission induction chemotherapy. There is no role for maintenance therapy in AML.
In summary, recommendations for HSCT in AML rely heavily on risk-stratified cytogenetics (Box 3). In patients with good-risk cytogenetics, induction followed by postremission chemotherapy has shown outcomes superior to those of HSCT, with lower treatment-related mortality. There is minimal role for autologous HSCT for those patients who relapse. For those with intermediate-risk cytogenetics, age is often a determining factor, because the risk of treatment-related mortality increases with age. For these patients, treatment options include allogeneic transplantation for those with sibling donors and postremission chemotherapy, without clear benefit for one approach compared with the other. For those with poor-risk cytogenetics, allogeneic transplantation with a sibling or matched unrelated donor can be anticipated immediately following induction chemotherapy.
Of note, gemtuzumab ozogamicin (Mylotarg) was approved by the U.S. Food and Drug Administration for use in refractory AML. Gemtuzumab ozogamicin, an anti-CD33 immunotoxin conjugate, was shown to have a 30% response rate (complete response plus partial response) in older AML patients in first relapse, with their first remission having lasted 6 months or longer. However, this drug was withdrawn from the United States market in October 2010 due to excessive adverse events without clear support of initial benefits seen. This medication is only available under investigation protocol. New agents in studies now are nucleoside analogs (cladribine, clofarabine) and hypomethylating agents (azacitadine and decitabine).
The treatment of APL differs from the recommendations for AML. Instead, ATRA (45 mg/m2/day divided into two doses), which promotes differentiation of leukemic promyelocytes into mature cells, has been shown to improve disease-free survival and overall survival compared with chemotherapy alone. ATRA, along with an anthracycline and cytarabine, is currently the standard up-front therapy for patients with APL. A significant complication of APL treatment is APL differentiation syndrome. This is a cardiopulmonary syndrome, characterized by fever, respiratory distress, pulmonary changes (interstitial infiltrates, pleural effusion), pericardial effusion, hypotension, and acute renal failure. The mechanism behind this is the rapid differentiation of blasts into neutrophils. Differentiation syndrome occurs 25% of the time when ATRA is used alone, but is decreased to less than 10% when ATRA is used concurrently with chemotherapy. There are no clear factors linked to differentiation syndrome. Corticosteroids are the mainstay course of treatment. APL is also linked with coagulopathy complications of disseminated intravascular coagulopation and increased fibrinolysis. Patients need to be monitored very carefully and treated immediately. Despite these potential complications, the complete remission rate of APL is quite high, ranging from 70% to 95%. Arsenic trioxide has now been incorporated into the immediate post-remission setting based on the results of a randomized U.S. Intergroup study in which patients receiving this agent had improved disease-free survival. APL is the only AML subtype in which maintenance therapy (ATRA) is standard.
Back to Top
Over the past few decades, success in the treatment of AML has improved only modestly for patients younger than 60 years. In 1966, the median survival of adult patients with AML was 40 days. Today, AML patients younger than 60 years have complete response rates of 70% to 80% after induction chemotherapy. Overall survival, however, remains at only about 50% for those who go into a complete remission, or 30% to 40% overall. In 1998, the MRC AML 10 trial found that patients could be separated into three prognostic groups—favorable, intermediate, and adverse—defined by pretreatment cytogenetics. Overall survival at 5 years was found to be 65%, 41%, and 14%, respectively. If a patient undergoes an allogeneic HSCT while in first remission, the complete response rate ranges from 45% to 65%, although patient selection influences these outcomes.
Most relapses occur within 2 years of diagnosis, and the prognosis of relapsed disease is quite poor. In relapsed AML, complete response after allogeneic HSCT is 35% or lower. These patients should be considered for investigation trials. The prognosis for older patients remains quite poor. In the MRC AML 8 trial, the remission rate was 70% for patients younger than 50 years, 52% for those 60 to 69 years old, but only 26% for those older than 70 years. One theory for such disparity is that neutropenia after chemotherapy lasts longer and is less well tolerated in older adults than in younger patients. Another possible answer is the finding that hematopoietic cells of older patients are derived from a leukemic clone at diagnosis, in contrast to normal stem cells in younger counterparts. It is clear that older adults have worse cytogenetics, and more expression of genes encoding for drug efflux pumps, which compromises chemotherapy efficacy. The use of granulocyte-monocyte colony-stimulating factors or granulocyte colony stimulating factors reduce the period of neutropenia and the duration of hospitalization by approximately two days; unfortunately, this has not translated into improved overall survival or a decrease in infectious complications. Therefore, their use is not indicated.
Back to Top
- Acute myeloid leukemia (AML) represents a group of clonal hematopoietic stem-cell disorders.
- The incidence rate of AML increases with age.
- A diagnosis of AML requires 20% or more leukemic myeloid blasts.
- Pretreatment cytogenetics are useful in determining prognosis and appropriate treatment.
Back to Top
- Bullinger L, Döhner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350:1605–1616.
- Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) [published online ahead of print August 1, 2002]. Blood 2002; 100:4325–4336. doi:10.1182/blood-2002-03-0772.
- Byrd JC, Ruppert AS, Mrozek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 2004; 22:1087–1094.
- Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87:89–99.
- Grigg AP, Szer J, Beresford J, et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 1999; 107:409–418.
- Grimwade D, Walker H, Oliver F, et al; on behalf of the Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92:2322–2333.
- Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992; 19:47–84.
- Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications [published online ahead of print January 10, 2011]. J Clin Oncol 2011; 29:475–486. doi:10.1200/JCO.2010.30.2554.
- Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med 1994; 331:896–903.
- Rees JK, Gray RG, Swirsky D, Hayhoe FG. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; 2:1236–1241.
- Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group [published online ahead of print September 25, 2003]. Blood 2004; 103:479–485. doi:10.1182/blood-2003-05-1686.
- Stone RM. Induction and postremission therapy: new agents. Leukemia 2003; 17:496–498.
- Stone RM, Berg DT, George SL, et al; for the Cancer and Leukemia Group B. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995; 332:1671–1677.
- Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337:1021–1028.
- Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99:759–767.
- Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes [published online ahead of print April 8, 2009]. Blood 2009; 114:937–951. doi:10.1182/blood-2009-03-209262.
Back to Top